Luminex Corp (LMNX) Tops Q1 EPS by 12c

Luminex Corp (NASDAQ: LMNX) reported Q1 EPS of $0.24, $0.12 better than the analyst estimate of $0.12. Revenue for the quarter came in at $56.6 million versus the consensus estimate of $55.31 million.

"We began 2014 with a quarter of solid financial performance, driven by strong growth in our assay business as highlighted above. We are optimistic about the continued prospects and future success of our assay segment, given our current portfolio and pipeline," said Patrick J. Balthrop, president and chief executive officer of Luminex. "We are also pleased with the traction we are achieving in the adoption of our new products and their performance versus competition; principally our xTAG® infectious disease panels and our new pharmacogenomics tests."

"In addition, our R&D team continues to achieve key development milestones with our pipeline products, including ARIES, our sample-to-answer real-time PCR instrument, which is on schedule and nearing initiation of clinical trials. As we prepare for the commercial launch of ARIES and our other exciting pipeline products throughout 2014, we will be showcasing them at industry trade shows and conferences demonstrating that the Company is positioned for strategic success."

For earnings history and earnings-related data on Luminex Corp (LMNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c